Olopatadine extended release - Sun Pharmaceutical Industries

Drug Profile

Olopatadine extended release - Sun Pharmaceutical Industries

Alternative Names: Olopatadine controlled release - Sun Pharmaceutical Industries; Olopatadine OD - Sun Pharmaceutical Industries

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator Ranbaxy Laboratories
  • Developer Sun Pharmaceutical Industries
  • Class Antiallergics; Antihistamines; Dibenzoxepins; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 22 Feb 2016 Discontinued - Phase-III for Seasonal allergic rhinitis in India (PO)
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
  • 20 Sep 2011 Ranbaxy Laboratories completes a phase III trial in Seasonal allergic rhinitis in India (CTRI/2010/091/001058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top